oru.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Immunological profile in cerebrospinal fluid of patients with multiple sclerosis after treatment switch to rituximab and compared with healthy controls
Dept of Pharmacology and Clinical Neuroscience, Neurology, Umeå University, Umeå, Sweden.
Unit of Research, Education and Development, Östersund Hospital, Region Jaämtland Härjedalen, Östersund, Sweden.
Dept of Pharmacology and Clinical Neuroscience, Neurology, Umeå University, Umeå, Sweden.
Dept of Pharmacology and Clinical Neuroscience, Neurology, Umeå University, Umeå, Sweden.
Show others and affiliations
2018 (English)In: PLoS ONE, ISSN 1932-6203, E-ISSN 1932-6203, Vol. 13, no 2, article id e0192516Article in journal (Refereed) Published
Abstract [en]

Objective: To investigate changes in the cerebrospinal fluid (CSF) immunological profile after treatment switch from first-line injectables to rituximab in patients with relapsing-remitting MS (RRMS), and to compare the profile in MS patients with healthy controls (HC).

Method: Cerebrospinal fluid from 70 patients with clinically stable RRMS and 55 HC was analysed by a multiplex electrochemiluminescence method for a broad panel of cytokines and immunoactive substances before, and over a two-year period after, treatment switch to rituximab. After quality assessment of data, using a predefined algorithm, 14 analytes were included in the final analysis.

Results: Ten of the 14 analytes differed significantly in MS patients compared with HC at baseline. Levels of IP-10 (CXCL10), IL-12/23p40, IL-6, sVCAM1, IL-15, sICAM1 and IL-8 (CXCL8) decreased significantly after treatment switch to rituximab. The cytokines IP-10 and IL-12/IL-23p40 displayed the largest difference versus HC at baseline and also the largest relative reduction after therapy switch to rituximab.

Conclusion: We found significant changes in the immunological profile after therapy switch to rituximab in RRMS in the direction towards the values of HC. IP-10 and IL12/IL-23p40 deserve further studies as part of the immunopathogenesis of MS as well as for the mode of action of rituximab in MS.

Place, publisher, year, edition, pages
Public Library of Science , 2018. Vol. 13, no 2, article id e0192516
National Category
Neurology
Identifiers
URN: urn:nbn:se:oru:diva-65640DOI: 10.1371/journal.pone.0192516ISI: 000424517900086Scopus ID: 2-s2.0-85041734965OAI: oai:DiVA.org:oru-65640DiVA, id: diva2:1189584
Note

Funding Agencies:

County Councils of Västerbotten, Jämtland/Härjedalen and Örebro  

Unit of Research, Education and Development, Region Jämtland Härjedalen  JLL-379731  JLL-649011  JLL 467731 

Syskonen Perssons Donationsfond  JLL-467381  JLL-652541 

Available from: 2018-03-12 Created: 2018-03-12 Last updated: 2018-08-20Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textScopus

Authority records BETA

Gunnarsson, Martin

Search in DiVA

By author/editor
Gunnarsson, Martin
By organisation
School of Medical Sciences
In the same journal
PLoS ONE
Neurology

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf